The fact that hope is a key catalyst for the continuous progress and growing interest in M3 Biotechnology, Inc. and its drug that would modify neurodegenerative diseases is evidenced by the array of contacts received by the emerging biopharma company’s CEO, Leen Kawas, after her recent interview on the national radio program Trader’s Network.
The interview on Clear Channel iHeart Business Radio focused on M3’s novel platform of drugs that could reverse the course of diseases like Parkinson’s and Alzheikmer’s spurred emails and telephone calls to Kawas from around the U.S. and Canada.
IHeart host and interviewer Michael Yorba focused during much of his Q and A conversation with Kawas, on the activation of growth factors, a process that represents the key to the drug’s action.
But Yorba, during the 30-minute interview, also sought to bring out for listeners Kawas’ background as a Jordanian who was already a practicing pharmacist in her own country when she decided science offered more exciting and relevant opportunities so she came to the U.S. to get her PhD.
It was then, she told him, that she became involved with development process for the drug and within a short period of time, was tapped to be the CEO and oversee the company’s fund raising and advancement toward the first clinical trials.
The initial fund-raising round had not yet been completed at the time of the interview, but Kawas expressed confidence that the seed round would be oversubscribed, which has turned out to be the case.
Yorba, whose interviews on the six-year-old program are with CEOs from a wide range of backgrounds and industries, emphasized for his listeners that Kawas’, unique scientific and medical knowledge give her the credibility to lead the company in its next research-intensive phase.”
And he expressed the view that “Dr. Kawas’ goal and passion is entrepreneurship that leads to disease modifying pharmaceuticals that address critical unmet medical needs.”
It was soon after the interview that the emails began arriving and she insisted that each person who was reaching out, many asking to be personally involved at the point clinical trials get underway, deserved to connect with her personally.
“Although when clinical trials start we will have physicians determining the inclusion criteria for the trials, it is not M3’s decision, we will try and keep the patients informed about our progress. Patients and the huge unmet medical need is what motivates M3’s team to keep going” Kawas adds.